MassDevice2d
Johnson & Johnson has positive dual-energy ablation data
Johnson & Johnson MedTech (NYSE: JNJ) announced 12-month data from its SmartfIRE clinical trial of the ThermoCool SmartTouch ...
Baylor College of Medicine1mon
Thyroid Radiofrequency Ablation (RFA)
Using a radiofrequency generator, your doctor allows a carefully controlled amount of energy to flow through the electrode into the tissue to ablate the nodule. With the sustained RFA thermal heat, ...
Nasdaq22d
Autonomix Medical Achieves Design Lock for Apex 6 Radiofrequency Generator, Advances Towards U.S. Clinical Trials for Pancreatic Cancer Pain Treatment
The Apex 6 Generator aligned with the RF generator specifications required for Autonomix’s Sensing and RF Ablation System and provided a cost effective, de-risked approach to accelerating ...
Revolutionizing Medical Devices: How Ablation Technologies Are Transforming Minimally Invasive Treatments
Somashekharayya Hiremath said As an inventor, I have contributed to multiple projects and patents, shaping energy-based ...
Business Insider22d
Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation
The Apex 6 Generator aligned with the RF generator specifications required for Autonomix’s Sensing and RF Ablation System and provided a cost effective, de-risked approach to accelerating ...
Applied Clinical Trials Online1d
Thermocool Smarttouch SF Catheter Demonstrates High Efficacy in Patients with Atrial Fibrillation
In the SmartfIRE study, the Thermocool Smarttouch SF catheter showed an 86.9% effectiveness rate among patients treated with high adherence to recommended ablation parameters.
PharmiWeb4d
Johnson & Johnson MedTech Presents Pivotal 12-Month Effectiveness and Safety Data from SmartfIRE Study at 2025 EHRA Congress
SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy ...
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, ...
Mena FN22d
Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials In 2025 With Completed Integration Of Apex 6 Generator For Transvascular Ablation
The Apex 6 Generator aligned with the RF generator specifications required for Autonomix's Sensing and RF Ablation System and provided a cost effective, de-risked approach to accelerating platform ...